What the Evidence Says

Ibogaine is a psychoactive alkaloid associated with the iboga plant. Its active metabolite, noribogaine, has also drawn interest because its pharmacology and duration differ from the parent compound. For background on the compound itself, the ibogaine overview describes its history and pharmacologic context, but it should not be read as evidence of treatment benefit.

For alcohol use disorder (AUD), the central research questions are practical: whether a defined intervention changes abstinence, drinking days, heavy-drinking days, craving scores, or related outcomes; for whom; compared with what; and with what adverse events. The broader ibogaine and alcohol evidence overview provides context for these questions, while this page focuses on how to weigh the underlying studies.

Some discussion also extends to related compounds and derivatives intended to separate possible therapeutic effects from ibogaine’s risks. That distinction matters. A finding about a derivative, an animal model, or a metabolite is not automatically a finding about ibogaine in people with AUD.

Strength of evidence: hypothesis-generating. Preclinical research may examine alcohol intake, reward-related behavior, withdrawal-like effects, receptor activity, or drug metabolism in cells and animals. Such work can help frame a rationale for studying ibogaine, noribogaine, or derivatives, but model outcomes do not map cleanly onto sustained recovery, functioning, or safety in people.

Noribogaine is often discussed separately because it persists longer than ibogaine and may have different effects across biological targets. Those differences are reasons for careful research, not reasons to assume a clinical advantage. Claims about mechanisms should be kept distinct from demonstrated outcomes in adequately designed human trials.

It is also easy for broad ibogaine claims to spill into unrelated conditions. A page about ibogaine treatment for Parkinson’s, for example, addresses a different condition and cannot answer whether an intervention changes alcohol-related outcomes. Condition-specific evidence is necessary.

Strength of evidence: safety concern is material. Ibogaine has been associated with serious risks, including cardiac rhythm concerns, neurologic effects, and interactions with substances or medicines. These risks complicate study design and interpretation. They also mean that a claim of possible benefit cannot be assessed apart from screening, monitoring, contraindications, and adverse-event reporting.

The U.S. Food and Drug Administration’s investigational new drug application information explains the pathway through which research programs may seek to study investigational drugs in people. Reports of 2026 FDA-cleared noribogaine research programs refer to permission to conduct specified research, not FDA approval of a treatment for AUD.

Commercial language can make that distinction hard to see. References to an ibogaine clinic in Mexico, ibogaine treatment in Texas, or an ibogaine treatment facility should be evaluated as service claims, not as substitutes for transparent trial data, regulatory status, or medical guidance.